PLN-74809 Emerging Drug Insight

“PLN-74809 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about PLN-74809 for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF) in the seven major markets. A detailed picture of the PLN-74809 in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the PLN-74809. The report provides insights about the PLN-74809 Mechanism of Action, dosage, and administration, as well as research and development, including regulatory milestones, along with other developmental activities. Furthermore, it also includes future market assessments, such as the PLN-74809 market forecast analysis in the 7MM, SWOT analysis, analysts’ views, a comprehensive overview of market competitors, and a brief overview of other emerging therapies.

PLN-74809 Drug Summary

PLN-74809, Pliant Therapeutics’ lead program, is an oral, small-molecule, dual selective inhibitor of αVβ1/αVβ6 being developed for IPF and primary sclerosing cholangitis (PSC). These integrin’s cause upstream activation of TGF-β1 in actively fibrotic tissue. Inhibition of these integrin will block TGF-β1 activation, thereby preventing the growth of fibrotic tissue within the lung and bile ducts. Pliant Therapeutics is currently evaluating PLN-74809 in two Phase IIa trials in patients with IPF and one in patients with PSC.

The Phase IIa PET trial will evaluate the safety, tolerability, and target engagement of PLN-74809 in IPF patients. The company expects to report the preliminary data of INTEGRIS-IPF Phase IIa trial by the first half of 2021. The other Phase IIa trial evaluating PLN-74809 at 320 mg for 6 months is currently enrolling patients with IPF. As per the company, PLN-74809 has shown favorable tolerability and pharmacokinetic profile in Phase I trials. The company believes that good oral bioavailability and long half-life are promising for potential once-daily dosing.

PLN-74809 Market Forecast Report Scope

The report provides insights into:

• A comprehensive product overview including the description, PLN-74809 mechanism of action, dosage and administration, research and development activities in Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF).
• Elaborated details on PLN-74809 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the PLN-74809 research and development activities in Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF) across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around PLN-74809.
• The report contains forecasted PLN-74809 Sales for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF) till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF).
• The PLN-74809 Market Size Report also features the SWOT analysis with analyst views for PLN-74809 in Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF).

PLN-74809 Methodology

The PLN-74809 Market Forecast Report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and PLN-74809 Sales Data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

PLN-74809 Market Analytical Perspective by DelveInsight

In-depth PLN-74809 Market Assessment

This report provides a detailed market assessment of PLN-74809 for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted PLN-74809 Sales Data.

PLN-74809 Clinical Trials Assessment

The report provides the PLN-74809 Clinical Trials information for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF) covering trial interventions, trial conditions, trial status, start and completion dates.

PLN-74809 Market Forecast Report Highlights 

• In the coming years, the market scenario for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug PLN-74809 manufacturers to penetrate more into the market.  
• The PLN-74809 Companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence PLN-74809 dominance.
• Other emerging products for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF) are expected to give tough market competition to PLN-74809 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of PLN-74809 in Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF).
• Our in-depth analysis of the forecasted PLN-74809 Sales Data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the PLN-74809 in Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF).
• Analyze PLN-74809 Cost, pricing trends, and market positioning to support strategic decision-making in the Pridopidine Market Landscape.

Key Questions

• What is the product type, route of administration, and PLN-74809 Mechanism of Action?
• What is the PLN-74809 Clinical Trials status of the study related to Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the PLN-74809 development?
• What are the key designations that have been granted to PLN-74809 for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF)?
• What is the forecasted market scenario of PLN-74809 for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF)?
• What are the forecasted PLN-74809 Sales in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to PLN-74809 for Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF)?
• Which are the late-stage emerging therapies under development for the treatment of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF)?

Stay updated with us for Recent Articles @ New DelveInsight Blogs